The authors of "ALK-Targeted Therapy for Lung Cancer: Ready for Prime Time," in this issue of ONCOLOGY, address the newest developments in the field of targeted therapies for advanced non–small-cell lung cancer (NSCLC).
Vassiliki A. Papadimitrakopoulou, MD
Advertisement
Articles by Vassiliki A. Papadimitrakopoulou, MD
Advertisement
Latest Updated Articles
- The Future of NSCLC: Molecular Profiles Guiding Treatment Decisions
Published: June 14th 2011 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
3
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
4
Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC
5
